Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of improving killing effect of CIK cells on cancer cells

A technology of cancer cells and cells, which is applied in the medical field, can solve the problems of limited number of cells, short cell culture time, and low ratio, and achieve the effect of increasing the ratio of effective targets and promoting killing activity

Inactive Publication Date: 2015-02-18
合肥凤凰肿瘤医院
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The activation technology of CIK cells usually uses CD3 monoclonal antibody, interleukin-1, interleukin-2 and interferon INF-γ for activation and expansion. The effect of cell expansion is not satisfactory, and many units want to reduce the cost of culture The cell culture time is short, and the culture time of individual reports is only 2-3 days, so the number of cells obtained is limited, and the proportion of effective targets (CIK: cancer cells) is low, which is difficult to meet the needs of clinical treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of improving killing effect of CIK cells on cancer cells
  • Method of improving killing effect of CIK cells on cancer cells
  • Method of improving killing effect of CIK cells on cancer cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] The method for improving the killing effect of CIK cells on cancer cells specifically comprises the following steps:

[0029] During the induction of CIK cells, CD3 monoclonal antibody, interleukin-1, interleukin-2, interferon IFN-γ and interleukin-24 were added.

[0030] In the method for improving the killing effect of CIK cells on cancer cells provided by the present invention, the CD3 monoclonal antibody and IFN-γ are necessary for each scheme, and the CD3 monoclonal antibody plays a role of mitogen activity and can be combined with T Cross-linking CD3 on the cell surface induces its activation; interferon IFN-γ can induce the synthesis of interleukin-1 and other factors. The main difference between different schemes lies in the difference of interleukin. At present, researchers are working on improving the activity of CIK to kill tumor cells. Some of them add interleukin-7, interleukin-12 or interleukin-15, etc. Reports on cell modification by genetic modification...

Embodiment 2

[0035] Based on the foregoing embodiments, the present invention has also made the following improvements:

[0036] During the induction of CIK cells, when CD3 monoclonal antibody, interleukin-1, interleukin-2 and interferon INF-γ are added, the specific order is as follows:

[0037] Add CD3 monoclonal antibody to CIK cells;

[0038] Add interferon IFN-γ and interleukin-24;

[0039] After 24 hours, interleukin-1 and interleukin-2 were added.

[0040] Among them, adding interleukin-1 and interleukin-2 after 24 hours also includes:

[0041] Interleukin-2, interferon INF-γ, and interleukin-24 were supplemented again at each passage expansion.

[0042] The passage includes at least 5 times.

[0043] Among them, the amount of interleukin-24 added depends on the amount of CIK cells. In order to improve the induction effect, it is necessary to keep the concentration of interleukin-24 added in the culture medium at 1000IU / mL. Usually, the concentration of CIK cells stay at 10 6 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medical treatment, in particular to a method of improving the killing effect of CIK cells on cancer cells. The method of improving the killing effect of the CIK cells on the cancer cells specifically comprises the following steps: in the process of inducing the CIK cells, a CD3 monoclonal antibody, interleukin-1, interleukin-2, interferon IFN-gamma and interleukin-24 are added. By means of the method of improving the killing effect of the CIK cells on the cancer cells, the effect-target ratio is increased, and the killing activity to tumor cells is promoted.

Description

technical field [0001] The invention relates to the medical field, in particular to a method for improving the killing effect of CIK cells on cancer cells. Background technique [0002] Cytokine-induced killer cells (CIK cells) are a group of heterogeneous cells obtained by co-inducing human peripheral blood mononuclear cells with various cytokines in vitro. A large number of studies have shown that CIK cells are a new type of non-major histocompatibility complex (MHC)-restricted immune effector cells with high efficiency and broad-spectrum anti-tumor activity. LAK, CTL, and TIL have stronger proliferative ability and cytotoxicity, and have no MHC restriction, so they have become the research hotspots of tumor biotherapy in the past ten years. [0003] The activation technology of CIK cells usually uses CD3 monoclonal antibody, interleukin-1, interleukin-2 and interferon INF-γ for activation and expansion. The effect of cell expansion is not satisfactory, and many units wan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N5/078
Inventor 王志华
Owner 合肥凤凰肿瘤医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com